Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Chief Operating Officer | March 20, 2025 | March 24, 2025 |
| Damora Therapeutics, Inc.DMRA · Entity 4602 | Director | March 23, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date March 20, 2025 · Filed March 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 10,544 |
Ending reported balance
After 2025-03-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-03-20 · Exercise / conversion · Acquired 3,750 · Balance 12,258 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Row 2 · 2025-03-21 · Sale · Disposed 1,714 · Balance 10,544 F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,250 |
Reported balance
After 2025-03-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-20 · Exercise / conversion · Disposed 3,750 · Balance 11,250 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3: This restricted stock unit award was granted on March 20, 2024 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. |
| Common SharesSEC Table I · non-derivative | IndirectThe Julianne Bruno 2022 GRAT | 7,088 |
Reported balance
Holding disclosure · report date 2025-03-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,088 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3: This restricted stock unit award was granted on March 20, 2024 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.
Damora Therapeutics, Inc.
Report date March 23, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.05 · Expires 2036-03-23 | Direct | 37,313 |
Reported balance
After 2026-03-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-23 · Grant · Acquired 37,313 · Balance 37,313 F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Mar 25, 2026 17:57 UTC | Damora Therapeutics, Inc. DMRA · Entity 4602 | GrantStock Option (right to buy) · Derivative | 37,313 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001193125-26-124455 · ownership.xml · derivative · entry 1 Bruno Julianne · CIK 0002019645 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,313 Underlying: Common Stock · 37,313 shares Expires 2036-03-23 F1 · derivative.exercise_date: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 06:05 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionSeries C Preferred Stock · Derivative | 129 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-047537 · ownership.xml · derivative · entry 2 Bruno Julianne · CIK 0002019645 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 129,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. F1 · kind: On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share ("Series C Preferred Stock") (the "Requisite Stockholder Approval"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 129 shares of Series C Preferred Stock held by the Reporting Person were converted into 129,000 shares of Common Stock. The securities of the Issuer held by the Reporting Person, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days F2 · kind: (Continued from footnote 1) following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026. F3 · derivative.exercise_date: Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. F3 · derivative.expiration_date: Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 06:05 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-047537 · ownership.xml · nonDerivative · entry 1 Bruno Julianne · CIK 0002019645 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share ("Series C Preferred Stock") (the "Requisite Stockholder Approval"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 129 shares of Series C Preferred Stock held by the Reporting Person were converted into 129,000 shares of Common Stock. The securities of the Issuer held by the Reporting Person, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days F2 · kind: (Continued from footnote 1) following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,714 | $41.23 | $70,668.22 |
DisclosureSEC source: 0000950170-25-043974 · ownership.xml · nonDerivative · entry 2 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,544 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-043974 · ownership.xml · derivative · entry 4 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Shares · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-043974 · ownership.xml · nonDerivative · entry 1 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-041468 · ownership.xml · derivative · entry 2 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Shares · 27,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 36,666 | $0.00 Strike: $42.12 | $0.00 |
DisclosureSEC source: 0000950170-25-041468 · ownership.xml · derivative · entry 1 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,666 Underlying: Common Shares · 36,666 shares Expires 2035-03-14 F1 · derivative.exercise_date: This option was granted on March 14, 2025 with respect to 36,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025. Read SEC document |
| March 12, 2025 Filed Mar 12, 2025 19:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 190 | $43.32 | $8,230.80 |
DisclosureSEC source: 0000950170-25-038214 · ownership.xml · nonDerivative · entry 4 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,508 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 19:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038214 · ownership.xml · derivative · entry 7 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 1,740 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F4 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 1,740 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 19:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038214 · ownership.xml · nonDerivative · entry 3 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 19:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,198 | $42.42 | $50,819.16 |
DisclosureSEC source: 0000950170-25-038214 · ownership.xml · nonDerivative · entry 2 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,263 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 19:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 2,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038214 · ownership.xml · derivative · entry 6 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,796 Underlying: Common Shares · 2,399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 9,593 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 9,593 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 19:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038214 · ownership.xml · nonDerivative · entry 1 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 333 | $52.80 | $17,582.40 |
DisclosureSEC source: 0000950170-25-023387 · ownership.xml · nonDerivative · entry 2 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,062 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023387 · ownership.xml · derivative · entry 4 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650 Underlying: Common Shares · 650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 2,600 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 2,600 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023387 · ownership.xml · nonDerivative · entry 1 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 18,333 | $0.00 Strike: $49.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115695 · ownership.xml · derivative · entry 1 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Shares · 18,333 shares Expires 2034-10-16 F1 · derivative.exercise_date: This option was granted on October 16, 2024 with respect to 18,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 16, 2024. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,366 | $56.09 | $188,798.94 |
DisclosureSEC source: 0000950170-24-076916 · ownership.xml · nonDerivative · entry 2 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,745 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 7,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-076916 · ownership.xml · derivative · entry 4 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 7,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on December 14, 2021 with respect to 7,000 Common Shares, with 100% of the shares vesting on June 20, 2024. F3 · derivative.expiration_date: This restricted stock unit award was granted on December 14, 2021 with respect to 7,000 Common Shares, with 100% of the shares vesting on June 20, 2024. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 17:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 7,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-076916 · ownership.xml · nonDerivative · entry 1 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| May 23, 2024 Filed May 24, 2024 16:15 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-064607 · ownership.xml · derivative · entry 1 Bruno Julianne · CIK 0002019645 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: This restricted stock unit award was granted on May 23, 2024 with respect to 20,000 Common Shares, with 100% of the shares vesting on May 23, 2026. F2 · derivative.expiration_date: This restricted stock unit award was granted on May 23, 2024 with respect to 20,000 Common Shares, with 100% of the shares vesting on May 23, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.